307 related articles for article (PubMed ID: 11127873)
1. Identification and biological activity of the active metabolite of clopidogrel.
Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
[TBL] [Abstract][Full Text] [Related]
2. P2Y12, a new platelet ADP receptor, target of clopidogrel.
Herbert JM; Savi P
Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
[TBL] [Abstract][Full Text] [Related]
3. P2y(12), a new platelet ADP receptor, target of clopidogrel.
Savi P; Labouret C; Delesque N; Guette F; Lupker J; Herbert JM
Biochem Biophys Res Commun; 2001 May; 283(2):379-83. PubMed ID: 11327712
[TBL] [Abstract][Full Text] [Related]
4. A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation.
Brandt JT; Payne CD; Wiviott SD; Weerakkody G; Farid NA; Small DS; Jakubowski JA; Naganuma H; Winters KJ
Am Heart J; 2007 Jan; 153(1):66.e9-16. PubMed ID: 17174640
[TBL] [Abstract][Full Text] [Related]
5. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
Savi P; Laplace MC; Maffrand JP; Herbert JM
J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
[TBL] [Abstract][Full Text] [Related]
6. Platelet aggregometry and receptor binding to predict the magnitude of antithrombotic and bleeding time effects of clopidogrel in rabbits.
Wong PC; Crain EJ; Watson CA; Jiang X; Hua J; Bostwick JS; Ogletree ML; Schumacher WA; Rehfuss R
J Cardiovasc Pharmacol; 2007 May; 49(5):316-24. PubMed ID: 17513951
[TBL] [Abstract][Full Text] [Related]
7. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
Weber AA; Reimann S; Schrör K
Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
[TBL] [Abstract][Full Text] [Related]
8. Stereoselective inhibition of human platelet aggregation by R-138727, the active metabolite of CS-747 (prasugrel, LY640315), a novel P2Y12 receptor inhibitor.
Hasegawa M; Sugidachi A; Ogawa T; Isobe T; Jakubowski JA; Asai F
Thromb Haemost; 2005 Sep; 94(3):593-8. PubMed ID: 16268477
[TBL] [Abstract][Full Text] [Related]
9. Clopidogrel inhibits platelet-leukocyte adhesion and platelet-dependent leukocyte activation.
Evangelista V; Manarini S; Dell'Elba G; Martelli N; Napoleone E; Di Santo A; Lorenzet PS
Thromb Haemost; 2005 Sep; 94(3):568-77. PubMed ID: 16268474
[TBL] [Abstract][Full Text] [Related]
10. Functional variability of platelet response to clopidogrel correlates with P2Y(12) receptor occupancy.
Bal Dit Sollier C; Berge N; Boval B; Hovsepian L; Drouet L
Thromb Haemost; 2009 Jan; 101(1):116-22. PubMed ID: 19132197
[TBL] [Abstract][Full Text] [Related]
11. Repeat oral dosing of prasugrel, a novel P2Y12 receptor inhibitor, results in cumulative and potent antiplatelet and antithrombotic activity in several animal species.
Niitsu Y; Sugidachi A; Ogawa T; Jakubowski JA; Hashimoto M; Isobe T; Otsuguro K; Asai F
Eur J Pharmacol; 2008 Jan; 579(1-3):276-82. PubMed ID: 17996866
[TBL] [Abstract][Full Text] [Related]
12. Design, synthesis, and inhibition of platelet aggregation for some 1-o-chlorophenyl-1,2,3,4-tetrahydroisoquinoline derivatives.
Yang J; Hua WY; Wang FX; Wang ZY; Wang X
Bioorg Med Chem; 2004 Dec; 12(24):6547-57. PubMed ID: 15556771
[TBL] [Abstract][Full Text] [Related]
13. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
[TBL] [Abstract][Full Text] [Related]
14. P2Y receptor antagonists in thrombosis.
Boeynaems JM; van Giezen H; Savi P; Herbert JM
Curr Opin Investig Drugs; 2005 Mar; 6(3):275-82. PubMed ID: 15816504
[TBL] [Abstract][Full Text] [Related]
15. The antiaggregating activity of clopidogrel is not affected by N-acetyl L-cysteine.
Lalé A; Herbert JM; Savi P
Thromb Haemost; 2003 Nov; 90(5):839-43. PubMed ID: 14597979
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel versus prasugrel in rabbits. Effects on thrombosis, haemostasis, platelet function and response variability.
Wong PC; Crain EJ; Watson CA; Hua J; Schumacher WA; Rehfuss R
Thromb Haemost; 2009 Jan; 101(1):108-15. PubMed ID: 19132196
[TBL] [Abstract][Full Text] [Related]
17. A possible mechanism for the differences in efficiency and variability of active metabolite formation from thienopyridine antiplatelet agents, prasugrel and clopidogrel.
Hagihara K; Kazui M; Kurihara A; Yoshiike M; Honda K; Okazaki O; Farid NA; Ikeda T
Drug Metab Dispos; 2009 Nov; 37(11):2145-52. PubMed ID: 19704027
[TBL] [Abstract][Full Text] [Related]
18. Increased active metabolite formation explains the greater platelet inhibition with prasugrel compared to high-dose clopidogrel.
Payne CD; Li YG; Small DS; Ernest CS; Farid NA; Jakubowski JA; Brandt JT; Salazar DE; Winters KJ
J Cardiovasc Pharmacol; 2007 Nov; 50(5):555-62. PubMed ID: 18030066
[TBL] [Abstract][Full Text] [Related]
19. Analysis of platelet alpha2-adrenergic receptor activity in stable coronary artery disease patients on dual antiplatelet therapy.
Béres BJ; Tóth-Zsámboki E; Vargová K; László A; Masszi T; Kerecsen G; Préda I; Kiss RG
Thromb Haemost; 2008 Nov; 100(5):829-38. PubMed ID: 18989527
[TBL] [Abstract][Full Text] [Related]
20. ADP-induced platelet aggregation frequently fails to detect impaired clopidogrel-responsiveness in patients with coronary artery disease compared to a P2Y12-specific assay.
Schäfer A; Weinberger S; Flierl U; Eigenthaler M; Störk S; Walter U; Ertl G; Bauersachs J
Thromb Haemost; 2008 Oct; 100(4):618-25. PubMed ID: 18841284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]